Altimmune, INC 10-Q quarterly reports

Altimmune reports substantial progress in its late-stage clinical trials for MASH and AUD, bolstered by a significant $211 million capital raise, while continuing to manage operational losses.

Altimmune, Inc. details its first-quarter 2026 financial performance and progress in its late-stage clinical trials for liver disease treatments, including pemvidutide.

Altimmune, a late clinical-stage biopharmaceutical company, reported a reduced net loss in Q3 2025, bolstered its cash position, and announced positive clinical trial updates for its lead drug candidate, pemvidutide, despite facing new legal challenges.

Altimmune, Inc. reported a narrower net loss in Q2 2025, driven by reduced R&D expenses, while its lead MASH drug, pemvidutide, demonstrated significant resolution rates in its Phase 2b trial.

Altimmune, a late clinical-stage biopharmaceutical company, announces its financial results for the first quarter of 2025 and provides an update on its business operations, including progress on its lead program, pemvidutide, and expansion into new indications.

Altimmune's Q3 2024 report highlights progress in its pemvidutide program, including the completion of an End-of-Phase 2 meeting with the FDA and the design of a Phase 3 registrational program for obesity.

Altimmune's Q2 2024 results show increased R&D spending on pemvidutide, a net loss of $49 million for the first six months, and ongoing legal challenges.

Altimmune reported a net loss of $24.4 million for the first quarter of 2024, with a focus on advancing its pemvidutide program and discontinuing HepTcell development.